Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
2,345
Views
2
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
Vicente Escudero-Vilaplanaa Hospital Gregorio Marañón, Madrid, Spainhttps://orcid.org/0000-0003-4417-8321
, Roberto Collado-Borrella Hospital Gregorio Marañón, Madrid, Spainhttps://orcid.org/0000-0001-7639-0082
, Javier De Castrob Hospital Universitario La Paz, Madrid, Spain
, Amelia Insac Hospital Clínico Universitario de Valencia, Valencia, Spainhttps://orcid.org/0000-0002-3438-6170
, Alex Martínezd Hospital Universitari Vall d’Hebron, Barcelona, Spain
, Elena Fernándeze OSI Bilbao-Basurto, Bilbao, Spainhttps://orcid.org/0000-0003-1624-8206
, Ivana Sullivanf Hospital de la Santa Creu i Sant Pau, Barcelona, Spainhttps://orcid.org/0000-0002-0434-3436
, Andrés Floresg Roche Farma S.A, Madrid, Spain
, Natalia Arrabalg Roche Farma S.A, Madrid, Spain
, David Carcedoh Hygeia Consulting, Madrid, SpainCorrespondence[email protected]
https://orcid.org/0000-0002-2809-7399
& https://orcid.org/0000-0002-2809-7399
Alba Manzanequei Hospital Universitari Mútua Terrassa, Terrassa, Spainhttps://orcid.org/0000-0002-7935-8317
show all
Pages 445-453
|
Received 26 Jan 2023, Accepted 03 Mar 2023, Published online: 30 Mar 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.